



November 27, 2025

The Manager- Listing **BSE Limited**Corporate Relationship Dept., 5th Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai – 400 001

The Manager- Listing

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block

Bandra – Kurla Complex, Bandra (E),

Mumbai – 400 051

Dear Sir/Madam,

<u>Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</u>

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Company has received an order from the Commissioner of Income-tax (Appeals) ("CIT(A)") issued under section 250 of the Income Tax Act, 1961 ("the Act") for the assessment year 2020-21, on November 26, 2025.

In this regard, please find the details as required under the SEBI Circular SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 attached herewith as **Annexure – A**.

Further, some time was spent in good faith for evaluation of the order.

Kindly take the above information on record.

Thanking You
For AstraZeneca Pharma India Limited

Manasa R Company Secretary

WEB: www.astrazeneca.com/india





<u>Annexure – A</u>

Sl. No.	Particulars	Details
1.	Name of the opposing party	Centralised Processing Centre ("CPC")
2.	Brief details of dispute/litigation	Company has received an order from the CIT(A) issued under section 250 of the Act for the assessment year 2020-21. The order has been passed pursuant to appeal filed by the Company against the intimation issued under section 143(1) of the Act for the captioned year. In the said intimation, erroneous addition of Rs. 13.11 crore was made by CPC. In the captioned order, the CIT(A) has directed the Assessing Officer to delete the addition made by CPC, post verifying the claim of the Company.
3.	Court/tribunal/agency where the litigation is filed	An appeal was filed before CIT(A) against which the CIT(A) has passed the captioned order. Now, the Company would take up the matter with the Assessing Officer to pass the order in line with the directions provided by the CIT(A).
4.	Expected financial implications, if any, due to compensation, penalty etc	The estimated favorable tax impact on account of the captioned CIT(A) order would be Rs. 3.30 crore (approx.).
5.	Quantum of claims, if any	NA

WEB: www.astrazeneca.com/india

TEL: +91 80 6774 9000